Contract research organization

PredxBio and Sirona Dx Join Forces to Revolutionize Drug Discovery and Development with SpaceIQ™ Leveraging Advanced Spatial Analytics and Explainable AI Solutions

Retrieved on: 
tisdag, april 2, 2024
TME, Algorithm, Immunotherapy, Drug discovery, Partnership, Patient, Tumor microenvironment, Doctor of Philosophy, Contract research organization, Biology, Drug development, Medical imaging

PITTSBURGH and PORTLAND, Ore., April 2, 2024 /PRNewswire-PRWeb/ -- PredxBio, Inc., a leader in spatially intelligent biology, and Sirona Dx, a leader in single cell multi-omics, analytical services, have announced a strategic partnership aimed at reshaping the landscape of drug discovery and development. This collaboration marks a pivotal moment in the industry, leveraging Explainable AI-Driven Spatial Biology with a groundbreaking new platform SpaceIQ™ to unlock the potential of genomic, proteomic, and transcriptomic data through advanced spatial analytics.

Key Points: 
  • This collaboration marks a pivotal moment in the industry, leveraging Explainable AI-Driven Spatial Biology with a groundbreaking new platform SpaceIQ™ to unlock the potential of genomic, proteomic, and transcriptomic data through advanced spatial analytics.
  • The partnership combines PredxBio's game changing spatial analytics platform, SpaceIQ™, with Sirona Dx's unparalleled expertise in multiplex assay development.
  • Through this strategic alliance, Sirona Dx and PredxBio will deliver advanced spatial analytics and explainable AI-powered decisions at scale, spanning the drug development continuum.
  • "Our combined expertise in multiplexing, explainable AI, and unbiased spatial analytics will revolutionize spatial biology, yielding unprecedented insights to enhance future immunotherapy approaches."

Contract Research Organization (CRO) Market size to grow by USD 63.35 billion from 2024-2028, Market Growth at 12.61% CAGR expected during the forecast period, Technavio

Retrieved on: 
onsdag, mars 20, 2024
ChromeOS, Software as a service, Science, Chronic condition, Infection, Laboratory, Clinical trial, European, USD, Regulation, Obesity, Biotechnology, Risk, Diabetes, CNS, DSM-IV codes, ROW, Contract research organization, Compound annual growth rate, TB, PPD, Central nervous system disease, Neurology, Medicine, Medication, Clinical, Science 37, Research, Acquisition, Cancer, Drug development, HIV/AIDS, DCT, Growth, Cardiology, Software, Messenger, Behavior, PPD, Inc., Malaria, Lung compliance, Fine chemical

By geography, the global contract research organization (cro) market is segmented into North America, Europe, Asia, and Rest of World (ROW).

Key Points: 
  • By geography, the global contract research organization (cro) market is segmented into North America, Europe, Asia, and Rest of World (ROW).
  • The report provides actionable insights and estimates the contribution of all regions to the growth of the global contract research organization (cro) market.
  • Growth of the Contract Research Organization (CRO) Market industry across North America, Europe, Asia, and Rest of World (ROW)
    Gain instant access to 17,000+ market research reports.
  • The global mRNA synthesis raw material market size is estimated to grow by USD 776.45 million at a CAGR of 4.93% between 2023 and 2028.

MCRA's Head of Healthcare Compliance to Serve on Michigan Board of Medicine

Retrieved on: 
onsdag, mars 20, 2024
Professional, CPCM, Ethics, Contract research organization, CHC, Licensure, Safety, Medicine, Pharmaceutical industry

Gretchen Whitmer of Michigan to represent the general public on the Board of Medicine.

Key Points: 
  • Gretchen Whitmer of Michigan to represent the general public on the Board of Medicine.
  • Mr. Abdallah states, "I am honored by the Governor's appointment to represent the people of Michigan and commissioning my expertise to the Board of Medicine during this tenure.
  • Anthony Viscogliosi, CEO of MCRA states, "Hassan's exemplary knowledge in the field of healthcare compliance makes him a perfect appointee to the Michigan Board of Medicine.
  • We at MCRA congratulate Hassan on this incredible achievement and look forward to seeing him bring his vast healthcare compliance and leadership experience to this important role."

TFS HealthScience Unveils Asia Pacific Expansion, Elevating Patient Access and Innovation

Retrieved on: 
tisdag, mars 12, 2024
Neurology, TFS, ChromeOS, Growth, Partnership, Patient, Contract research organization, Cultural diversity, Consultant, Fine chemical

LUND, Sweden, March 12, 2024 /PRNewswire/ -- TFS HealthScience ( TFS ) , a leading global Contract Research Organization (CRO), announces its expansion into the Asia Pacific (APAC) region, with the establishment of an operational base in Melbourne, Australia.

Key Points: 
  • LUND, Sweden, March 12, 2024 /PRNewswire/ -- TFS HealthScience ( TFS ) , a leading global Contract Research Organization (CRO), announces its expansion into the Asia Pacific (APAC) region, with the establishment of an operational base in Melbourne, Australia.
  • The APAC region presents a promising landscape for clinical research, with a diverse patient population encompassing various ethnicities, demographics, and medical conditions.
  • TFS recognizes the potential to contribute significantly to advancing medical knowledge and improving patient outcomes in this vibrant and growing market.
  • This strategic move not only broadens access to diverse patient populations and cutting-edge technologies but also leverages streamlined regulatory environments for faster, more efficient trial execution.

TFS HealthScience Unveils Asia Pacific Expansion, Elevating Patient Access and Innovation

Retrieved on: 
tisdag, mars 12, 2024
Neurology, TFS, ChromeOS, Growth, Partnership, Patient, Contract research organization, Cultural diversity, Consultant, Fine chemical

LUND, Sweden, March 11, 2024 /PRNewswire/ -- TFS HealthScience (TFS) , a leading global Contract Research Organization (CRO), announces its expansion into the Asia Pacific (APAC) region, with the establishment of an operational base in Melbourne, Australia.

Key Points: 
  • LUND, Sweden, March 11, 2024 /PRNewswire/ -- TFS HealthScience (TFS) , a leading global Contract Research Organization (CRO), announces its expansion into the Asia Pacific (APAC) region, with the establishment of an operational base in Melbourne, Australia.
  • The APAC region presents a promising landscape for clinical research, with a diverse patient population encompassing various ethnicities, demographics, and medical conditions.
  • TFS recognizes the potential to contribute significantly to advancing medical knowledge and improving patient outcomes in this vibrant and growing market.
  • This strategic move not only broadens access to diverse patient populations and cutting-edge technologies but also leverages streamlined regulatory environments for faster, more efficient trial execution.

Psyence Biomedical’s Subsidiary, Psyence Australia, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study

Retrieved on: 
onsdag, mars 6, 2024
Anxiety, Palliative care, Caregiver, Research, Quality of life, Terminal, Standard of care, Adjustment disorder, Contract research organization, World Health Organization, Patient, Clinical trial, Diagnosis, PBM, Psychotherapy, Adjustment, Nursing

NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (NASDAQ:PBM) ("Psyence Biomed" or the "Company") is pleased to announce that its wholly-owned subsidiary, Psyence Australia (Pty) Ltd ("Psyence Australia"), has received full approval from the Australian Health Research Ethics Committee (HREC) to initiate its planned Phase IIb study in Melbourne, Australia.

Key Points: 
  • NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (NASDAQ:PBM) ("Psyence Biomed" or the "Company") is pleased to announce that its wholly-owned subsidiary, Psyence Australia (Pty) Ltd ("Psyence Australia"), has received full approval from the Australian Health Research Ethics Committee (HREC) to initiate its planned Phase IIb study in Melbourne, Australia.
  • The study will examine the use of nature-derived psilocybin as a treatment for Adjustment Disorder due to a recent cancer diagnosis in the palliative care context.
  • Psyence Australia has partnered with a noted psychedelic Contract Research Organization (CRO), iNGENū Pty Ltd ("iNGENū"), to design and execute the clinical trial.
  • Psyence anticipates enrolling the first patient in Q2 2024 and expects the primary endpoint results to be available in 2025.

Intelligent Bio Solutions Partners with Cliantha Research to Conduct Clinical Study as Part of FDA 510(k) Pathway

Retrieved on: 
onsdag, februari 28, 2024
LC-MS/MS, Blood, Marketing, FDA, News, Trial of the century, DSR, Contract research organization, Classification, Intelligence, Partnership, Medical device

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its partnership with Cliantha Research , a full-service Clinical Research Organization (CRO), to perform a pharmacokinetic (PK) study forming part of the Company’s FDA 510(k) clinical study plan.

Key Points: 
  • NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its partnership with Cliantha Research , a full-service Clinical Research Organization (CRO), to perform a pharmacokinetic (PK) study forming part of the Company’s FDA 510(k) clinical study plan.
  • The fingerprint sweat specimen will be screened using INBS’ Intelligent Fingerprinting Drug Screening System comprising the Intelligent Fingerprinting Drug Screening Cartridge and DSR-Plus fluorescence reader and compared to the LC-MS/MS results.
  • The start of the clinical study plan marks an exciting milestone for the Company as it advances on its 510(k) pathway.
  • Harry Simeonidis, President and CEO at Intelligent Bio Solutions, commented, “We are pleased to share news of our partnership with Cliantha and progress on our 510(k) journey.

Novotech Publishes Duchenne Muscular Dystrophy Landscape Report to Support Biotech Research Planning

Retrieved on: 
onsdag, februari 28, 2024
Therapy, Genetic disorder, Investment, Clinical trial, DMD, SWOT, Duchenne muscular dystrophy, Muscular dystrophy, Prevalence, Contract research organization, RNA, Organization, Disease, Diagnosis, Male, Mutation, ROW, Epidemiology, Research, Pharmaceutical industry

BOSTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Novotech , the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has released today an industry-leading report on Duchenne Muscular Dystrophy (DMD) Clinical Trial Landscape .

Key Points: 
  • BOSTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Novotech , the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has released today an industry-leading report on Duchenne Muscular Dystrophy (DMD) Clinical Trial Landscape .
  • The Novotech research analyst team provides these expert reports monthly, completely free of charge.
  • They tackle the hurdles faced by biotech firms in specific therapeutic areas and discuss future paths in therapy and investment trends.
  • This comprehensive resource guides healthcare professionals, researchers, and organizations in navigating the complex clinical trial DMD landscape.

Calian Wins Contract to Support Clinical Trial for ZYUS Life Sciences’ Lead Drug Product Candidate

Retrieved on: 
tisdag, februari 20, 2024
CGY, Clinical trial, TSX, Pain, Data management, Learning, Safety, Contract research organization, Chronic pain, Patient, Knowledge, Medical writing, Partnership, Pharmaceutical industry

Calian's full-service Contract Research Organization (CRO) will apply its extensive clinical trial management experience to support a Phase 2 Clinical Trial for Trichomylin softgel capsules.

Key Points: 
  • Calian's full-service Contract Research Organization (CRO) will apply its extensive clinical trial management experience to support a Phase 2 Clinical Trial for Trichomylin softgel capsules.
  • “Calian will apply our industry-leading expertise to support this Phase 2 Clinical Trial and further ZYUS’ pursuit of transformational impact on patients’ lives,” says Derek Clark, President, Calian Health.
  • Calian will provide full-service, end-to-end expertise to support this trial, including medical writing, regulatory affairs, clinical operations, site monitoring, data management, medical monitoring and quality assurance.
  • By collaborating with an industry leading contract research organization with extensive experience in clinical trial management, we can leverage invaluable knowledge and expertise."

Managing Service Providers Including CRO and CMOs Oversight to Comply with ICH GCP R3 Training Course (April 18-19, 2024) - ResearchAndMarkets.com

Retrieved on: 
torsdag, februari 29, 2024
Science, Research, Pharmaceutical, Health, Outsourcing Business, Professional Services, Education, Training, ICH GCP, Consultant, RFP, Pharmacovigilance, Contract research organization, ICH, Biotechnology, CMOS, Fine chemical

The "Managing Service Providers including CRO (Contract Research Organisation) and CMOs oversight to comply with ICH GCP (Good Clinical Practice) R3 Training Course" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Managing Service Providers including CRO (Contract Research Organisation) and CMOs oversight to comply with ICH GCP (Good Clinical Practice) R3 Training Course" conference has been added to ResearchAndMarkets.com's offering.
  • A company's ability to identify and select the right CRO/ vendor for the right project and manage them efficiently and effectively will help to ensure compliance with the regulator's expectations.
  • You will also cover the techniques for successfully managing CROs/ vendors and the shared responsibilities required by the sponsor and the service provider.
  • The course is equally useful to CROs/other vendors and consultants to understand how to work effectively with sponsor organisations.